Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

ABSTRACT:

Background

Prostasin, a trypsin-like serine protease, is a channel-activating protease and major regulator of epithelial sodium channel-mediated sodium absorption. Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF).

Methods

To determine whether a topical formulation of camostat represents an efficacious and tolerable approach to reducing Na+ transport in the CF airway, we conducted a two-part randomized, double-blind, placebo-controlled, crossover, ascending single-dose study to evaluate the pharmacodynamics, safety, and pharmacokinetics of camostat administered through a nasal spray pump in subjects with CF. Nasal potential difference (PD) was measured before and after treatment, and safety and pharmacoki

SUBMITTER: Rowe SM 

PROVIDER: S-EPMC3707174 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature